Chelsea Therapeutics Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Charlotte NC United States (2004)
Status: Acquired by Lundbeck (2014)

Organization Overview

First Clinical Trial
2007
NCT00657046
First Marketed Drug
2014
droxidopa (northera)
First NDA Approval
2014
droxidopa (northera)
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chelsea Therapeutics, Inc.